SOLICITATION NOTICE
Q -- Sex Steroid Hormones and Metabolites in Relation to the Risk of Male Breast Cancer
- Notice Date
- 7/24/2012
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120111-LG
- Archive Date
- 8/22/2012
- Point of Contact
- Laura Glockner, Phone: 3014968607
- E-Mail Address
-
laura.glockner@nih.gov
(laura.glockner@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB), plans to procure on a sole source basis services from Laval University, Bioanalytical Services, CHUQ Research Center, 2705, boul. Laurier, Room T3-48, Quebec, QC, G1V 4G2, Canada, for the assessment of sex steroid hormones and SHBG in serum or plasma samples. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 the business size standard is $14.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI), National Institutes of Health (NIH) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The HREB has been investigating the role of a panel of androgens, estrogens and androgens metabolites in male breast cancer development. The purpose of this requirement is to measure sex steroid hormones in 420 subject samples using a combination of gas chromatography- mass spectrometry (GC-MS), liquid chromatography-tandem mass spectrometry (LC-MS) and enzyme-linked immunosorbent assay (ELISA) assays, and compare these levels between male breast cancer cases and matched controls. Laval University is the only known contractor that can quantitate the 12 required sex steroid hormones and SHBG using state of the art technologies (GC-MS or LC-MS for each hormone analyte, and ELISA for SHBG) using a total volume of just 0.7 ml of serum or plasma per patient, with coefficients of variations less than 10% for each analyte. Targets for quantitation in 420 serum or plasma samples and assay types include the following: i. Dehydroepiandrosterone (DHEA) using GC-MS ii. Androst-5-enediol (Delta-5diol) using GC-MS iii. Androstenedione (4-dione) using GC-MS iv. Testosterone (T) using GC-MS v. Dihydrotestosterone (DHT) using GC-MS vi. Androsterone (ADT) using GC-MS vii. Estrone (E1) using GC-MS viii. Estradiol (E2) using GC-MS ix. Androsterone glucuronide using LC-MS x. 3-androstanediol-17 glucuronide using LC-MS xi. 3-androstanediol-3 glucuronide using LC-MS xii. Sex Hormone Binding Globulin (SHBG) using ELISA This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on August 7, 2012. No electronic capability statements will be accepted (i.e. email or fax) an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Laura Glockner, Contract Specialist at laura.glockner@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120111-LG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120111-LG/listing.html)
- Record
- SN02814071-W 20120726/120725000800-05274da0f41e891a64c2dbcfbee2b511 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |